|
NCT00026312
|
Isotretinoin With or Without Dinutuximab, Aldesleukin and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
|
phase III
|
Completed
|
Yu AL et al., 2010 [6]
|
|
NCT01704716
|
High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)
|
phase III
|
Recruiting
|
Dobrenkov K & Cheung NK, 2014 [7]
|
|
NCT01822652
|
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
|
phase I
|
Active, not recruiting
|
Heczey A & Louis CU, 2013 [8]
|
|
NCT02395666
|
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
|
Phase 2
|
Active, not recruiting
|
Wallick CJ et al., 2005 [64]
|
|
NCT01586260
|
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
|
Phase 2
|
Active, not recruiting
|
Wallick CJ et al., 2005 [64]
|
|
NCT01059071
|
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
|
Phase 1
|
Completed
|
Wallick CJ et al., 2005 [64]
|
|
NCT02097810
|
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1 or ALK Molecular Alterations
|
phase I
|
Recruiting
|
Lee J et al., 2015 [83]
|
|
NCT01742286
|
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
|
phase I
|
Recruiting
|
Schulte JH et al., 2013 [69]
|
|
NCT01871805
|
A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
|
phase II
|
Active, not recruiting
|
McKeage K, 2015 [86]
|
|
NCT01049841
|
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
|
phase I
|
Active, not recruiting
|
Rodrik-Outmezguine VS et al., 2011 [104]
|
|
NCT01767194
|
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
|
Phase 2
|
Recruiting
|
Geoerger B et al., 2012 [105]
|
